Search results
Results From The WOW.Com Content Network
The Philippine Criminology Profession Act of 2018 November 15, 2018 [27] 11148 Kalusugan at Nutrisyon ng Mag-Nanay Act (lit. ' Health and Nutrition for Mother and Child Act ') November 29, 2018 [28] 11663 National Bible Day Act December 20, 2018 [29] 11665 Telecommuting Act December 20, 2018 [30] 11666 Philippine HIV and AIDS Policy Act of 2018
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
The drug policy of the Philippines is guided by the Comprehensive Dangerous Drugs Act of 2002 and is implemented by the Dangerous Drugs Board with its implementing arm, the Philippine Drug Enforcement Agency along with other member agencies. Aside from regulating and prohibiting the usage, sale, production of certain drugs, the 2002 law is ...
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. [ 5 ] [ 6 ] [ 11 ] [ 8 ] [ 12 ] Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, [ 6 ] and full approval in February 2023.
The Food and Drug Administration (FDA) of the Philippines, formerly the Bureau of Food and Drugs (BFAD / ˈ b iː f æ d /; 1982–2009), is a health regulatory agency under the Department of Health created on 1963 by Republic Act No. 3720, amended on 1987 by Executive Order 175 otherwise known as the "Food, Drugs and Devices, and Cosmetics Act", and subsequently reorganized by Republic Act No ...
In March 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda). [4] [5] In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is ...
Stating that contraception is a lie and "against the beginning of new life", the Philippine Medical Association also stressed that the "health risks of contraception to women are considerable; the list of side effects is long, and includes high blood pressure, strokes, increased incidence of some forms of cancer". [33]
The drug was reviewed and approved under the Food and Drug Administration’s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015, as a treatment (in combination with letrozole) for patients with estrogen receptor positive (ER+) advanced breast cancer. [10] This was an accelerated approval. [11]